Article Text

Download PDFPDF

European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners
  1. David Y Graham1,
  2. Hashem B El-Serag2
  1. 1 Medicine (111D), Baylor College of Medicine, Houston, Texas, USA
  2. 2 Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA
  1. Correspondence to Dr David Y Graham, Medicine (111D), Baylor College of Medicine, Houston, TX 77030, USA; dgraham{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


The authors report the results of a 5-year (2013–2018) audit of the effectiveness of Helicobacter pylori therapy in clinical practice in several regions of Europe.1 The study provides a contemporary prospective regarding empirical H. pylori treatment. Importantly, there was little centralised influence on choice of therapy apart from sending periodic updates, presenting updates at the meeting of the European H. pylori study group and including local feedback in the form of post-treatment testing for cure. The strengths of the report include the large sample size, representative population, and high level of complete data on treatment type, duration and follow-up. Overall, 30 394 patients from 27 European countries provided data on 21 533 first-line empirical H. pylori treatments using more than 100 different schemes. Antibiotic susceptibility data were obtained from 11% (2.7% to 16.7% in different regions). In that small sample, the prevalence of H. pylori resistance to clarithromycin and metronidazole was high (ie, 23% and 32%, respectively). Clarithromycin triple therapy was most commonly used but use declined over time from >50% in 2013–2015 to 32% in 2017–2018. The use of bismuth quadruple therapy was uncommon and varied markedly between regions but also tended to increase over time. They concluded that the management of H. pylori infection by European gastroenterologists was heterogeneous, suboptimal and discrepant with current recommendations.

There seems to be an ongoing slow paradigm shift from therapies identified by trial and error to therapies based on the principles of antimicrobial stewardship. This shift is also between two schools, which we call the What and the Why Schools of thought regarding planning and analysis of clinical trials. The What School’s primary approach uses comparisons between regimens often relying on meta-analysis to ask whether treatment A or B is superior irrespective of why or whether either reliably achieves a high cure rate. This has often led to recommendations to use A rather than B, when both produce poor results.2 The Why School focuses on attainment of a prespecified cure rate (eg, >95%); comparisons are rare, and are generally limited to head-to-head comparisons of proven highly reliable optimised regimens and use non-inferiority methods with both regimens expected to achieve high cure rates.3 This shift needs to be recognised, encouraged and expedited.

The authors also presented some comparative effectiveness data that involved comparisons of treatments between different populations but lacked both susceptibility data and randomisation. This approach is less powerful than clinical trials for making valid inferences. However, they report that concomitant therapy and bismuth quadruple therapy were generally more effective, but neither regimen reliably achieved cure rates expected of typical infectious disease therapies. The absence of resistance data is important for interpretation of comparisons because in the presence of resistance, the effectiveness with bismuth quadruple therapy depends on metronidazole dosage and especially on duration of therapy.4 The principles of antimicrobial stewardship also argue against use of concomitant therapy because all recipients receive at least one unnecessary antibiotic.5

The two most common causes of failure of previously highly effective therapies are poor adherence and antimicrobial resistance. Worldwide, H. pylori resistance to clarithromycin, metronidazole and fluoroquinolones has increased such that it has been recommended that their use in triple therapies be limited to susceptibility-guided therapy or areas of proven local effectiveness.6 Although susceptibility testing is not widely available, it is important to note that susceptibility patterns can be assessed directly, indirectly or can be implied. Direct assessment uses culture whereas indirect assessment involves molecular methods using DNA obtained from gastric biopsy or stool. Implied susceptibility patterns are based on clinical experience with proven locally highly effective regimens. In this report, the high failure rates and the pattern of failures is consistent with a high prevalence of resistance reported. The study used empirical therapy defined as H. pylori treatment prescribed without knowledge of its local effectiveness or susceptibility patterns. The principles of antimicrobial stewardship require empiric therapies to be highly effective, given only to patients likely to benefit and use strategies designed to ensure that the regime remains sustainable. The use of empirical therapies also implies ongoing surveillance (eg, test of cure, susceptibility testing, etc) so that if effectiveness declines, the empirical regimen can be rapidly replaced.

The future

The Hp-EuReg produced a landmark study of the current practices that shows that gastroenterology has largely failed in its efforts to guide practitioners to reliably cure this disease. Although neither the patients nor the physicians participating in this audit benefited significantly, the study provides a model to use when more reliable therapies become available. The Hp-EuReg might now refocus on introducing the principles of antimicrobial stewardship to identify therapies that are reliably highly effective. Such studies in China have been able to identify a number of reliably highly effective regimens that can be successfully used empirically.7 The recent advances in vonoprazan–amoxicillin dual therapy also offer promise of a simple highly effective empirical regimen for patients not allergic to penicillin.8 Finally, it is important to institute programmes of antimicrobial stewardship for H. pylori. The USA may have taken the lead in that the Centers for Medicare and Medicaid Services recently finalised a new regulation requiring all hospitals participating in its programmes to establish antimicrobial stewardship programmes by 30 March 2020.9 They also suggest using the US Centers for Disease Control documents regarding antimicrobial stewardship in hospitals with limited resources as a guide.10 These guidelines require creation and promotion of susceptibility-based treatment, tracking of antibiotic dispensing and setting targets for improvement (ie, monitoring and reporting).


The Hp-EuReg report highlights practice variability but also marks the slow transition of H. pylori therapy to therapies based on the principles of antimicrobial stewardship and reliable high eradication rates. Expediting these changes will require relinquishing cherished practices and ways of thinking about H. pylori therapy. Whether antimicrobial stewardship will be embraced by gastroenterology remains to be seen.



  • Contributors All authors have read and approved the final manuscript and each meets the criteria for authorship established by the International Committee of Medical Journal Editors and verify the validity of the results reported. We confirm that our paper has not been published in its current form or a substantially similar form (in print or electronically, including on a website), that it has not been accepted for publication elsewhere and that it is not under consideration by another publication.

  • Funding DYG and HE-S are supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338 which funds the Texas Medical Center Digestive Diseases Center.

  • Competing interests DYG is a consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel Helicobacter pylori therapies and has received research support for culture of H. pylori and is the PI of an international study of the use of antimycobacterial therapy for Crohn’s disease. HE-S is a consultant for Phathom Pharmaceuticals regarding novel H. pylori therapies.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Helicobacter pylori
    Olga P Nyssen Dmitry Bordin Bojan Tepes Ángeles Pérez-Aisa Dino Vaira Maria Caldas Luis Bujanda Manuel Castro-Fernandez Frode Lerang Marcis Leja Luís Rodrigo Theodore Rokkas Limas Kupcinskas Jorge Pérez-Lasala Laimas Jonaitis Oleg Shvets Antonio Gasbarrini Halis Simsek Anthony T R Axon György Buzás Jose Carlos Machado Yaron Niv Lyudmila Boyanova Adrian Goldis Vincent Lamy Ante Tonkic Krzysztof Przytulski Christoph Beglinger Marino Venerito Peter Bytzer Lisette Capelle Tomica Milosavljević Vladimir Milivojevic Lea Veijola Javier Molina-Infante Liudmila Vologzhanina Galina Fadeenko Ines Ariño Giulia Fiorini Ana Garre Jesús Garrido Cristina F Pérez Ignasi Puig Frederic Heluwaert Francis Megraud Colm O'Morain Javier P Gisbert On behalf of the Hp-EuReg Investigators Jen Hinojosa Inmaculada Santaella Nuria Fernandez Moreno Ilaria Maria Saracino Horacio Alonso Galán Almudena Durán Jennifer Fernandez Pacheco Miroslav Vujasinovic Rinaldo Pellicano Molinette Zdenko Kikec Pedro-Luis Gonzalez Cordero Maia Donday Polona Lampic Vid Leban Aleksander Gruncic Krajnc Natasa Brglez Jurecic Galyna Dmytrivna Fadieienko Lorena Lee Irene V Barbado Alfredo José Lucendo Alfredo José Lucendo Jesus Barrio RIo Hortega Tatiana Alekseevna Ilchishina Irina Voynovan Luis Ignacio Fernández-Salazar Jose María Huguet Pilar Canelles Aiman Silkanovna Sarsenbaeva Ines Modolell Consorci Pedro Almela Marina Roldán Lafuente Josep Maria Botargues Miguel Areia Luís Elvas Susana Isabel Alves Daniel Brito Ana Teresa Cadime Sandra Lúcia Madeira Saraiva Charalampos Tzathas Vassiliki Ntouli Alicia C Marin Cem Simsek Alba Rocco Juan Antonio Ortuño Tommaso Di Maira Sotirios D Georgopoulos Stephan Brackmann Vendel Kristensen Lovisenberg Blas Jose Gomez-Rodriguez Perminder Singh Phull Sergey Alekseyevich Monica Perona Rustam Abdulkhakov Deirdre McNamara Sinead M Smith Denise Elizabeth Brennan Marina Fedorovna Osipenko Cristobal de la Coba Pilar Varela Maria Anatolyevna Livzan Oleg V Zaytsev Vladislav Vladimirovich Tsukanov Alexander Viktorovich Vasyutin Olga Sergeevna Amelchugova Spiros Michopoulus Sergey Gennadievich Burkov Dan Dumitrascu Bogdan Ianosi Ingrid Prytz Berset Rafael Ruiz-Zorrilla Lopez Charo Antón Anne Courillon-Mallet Natasa Brglez Jurecic Judith Gomez-Camarero Manuel Jimenez-Moreno Ahmet Uygun Ian Leonard Phillip Beales Alain Huerta-Madrigal Javier Alcedo Mercè Barenys Francesco Franceschi Jean-Charles Delchier Liliana Silvia Pozzati Monika Augustyn Maja Seruga Miriam Hiestand Patric Mosler Zaza Beniashvili Doron Boltin Hubert Louis Ramon Pajares Natalia Valerievna Zakharova Natalia Nikolaevna Dekhnich Victor Asparuhov Kamburov Maria Pina Dore Lorena Sancho Oscar Núñez Katrine Dvergsnes Sørlandet Peter Malfertheiner Ana Campillo Miguel Fernandez-Bermejo Manuel Domínguez-Cajal José Luis Domínguez Jiménez Alicia Algaba Fernando Bermejo Borislav Vladimirov László Czakó Teresa Angueira Eduardo Iyo Ekaterina Yuryevna Larissa Tarasova Ludmila Grigorieva Judith Millastre Aldis Pukitis Valeriy Kryvy Roald Torp Albert Tomàs Edurne Amorena Fermin Estremera Rossen Nikolov Asghar Quasim Yury Aleksandrovich Kucheryavyy Natalia Baryshnikova Xavier Calvet Ariadna Figuerola Marco Romano Antonietta Gerarda Gravina Oscar Núñez Fazia Mana Pilar Sánchez-Pobre Zoya Spassova Jesús M González-Santiago Ricardo Marcos-Pinto F Wolfhagen Svetlana Cui Ivonne Leeuwenburgh Driffa Moussata Adi Lahat-zok Sergii Hryhorovych Rasmus Goll Tatyana Vasilyevna Juris Pokrotnieks Philippe Émile Nadiya Byelyayeva Marta Lozano Mette Wildner-Christensen Bengt Odman Yana Valerieva Alenka Forte Antonio Cuadrado Patrice Pienkowski Ilze Kikuste Dag Arne Lihaug Hoff Jane Moeller Hansen Konrads Funka Alla Kononova Sergey Kolbasnikov Michael Selgrad Jolanta Sumskiene Jonathan Hirsch Francisco Javier Zozaya Larequi Alain C Burette Nora Dancs Petz-Aladar Janne Rajala Herttoniemi Christina Reimer Diogo Libanio Pedro Pimentel-Nunes Ivailo Evstatiev Juozas Kupcinskas Mikhail Butov Peter Mensink T Tang Andrey Yurevich Baranovsky Natalya Marchenko Boris Bastens Lyudmila Mateva Dominique Lamarque Leonardo Henry Mario Ribeiro M ter Borg Alexander C Ford Enrique Medina Manuel Rodriguez-Tellez Francisco José Rancel Elisa Martin Carolina Torres Gonzalez Lissa Maria Franco Angel Lanas Pilar Canelles Noelia Alcaide Bruno Richard-Molard